Impact of AI-quantified fluid dynamics on visual outcomes over 5 years in patients with treatment-na&#xef;ve nAMD from the FRB! registry

Macular Diseases

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Ophthalmol Retina

Steinle NC, McCullough AJ, Silva FQ, Du W, Moini H, Singh RP

doi: 10.1016/j.oret.2024.12.018

Macular Diseases

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Br J Ophthalmol

Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, De Zanet S, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Parrado-Carrillo A, Moll-Udina A, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mishchuk A, Casaroli-Marano RP, Zarranz-Ventura J, from the FRB SPAIN-IMAGE Project Investigators

doi: 10.1136/bjo-2024-325615

Retinal Diseases

Clinical characteristics associated with complications and poor visual outcomes in ocular toxoplasmosis: Analysis of 853 patients: complications and visual outcomes in ocular toxoplasmosis

Am J Ophthalmol

de-la-Torre A, Mejía-Salgado G, Cifuentes-González C, Cuevas M, García S, Rangel CM, Durán C, Pachón-Suárez DI, Bustamante-Arias A, Rojas-Carabali W

doi: 10.1016/j.ajo.2025.02.027

Macular Diseases

Long-Term Natural History of Treatment-Naïve Geographic Atrophy in Age-Related Macular Degeneration

Transl Vis Sci Technol

Muth DR, Quérat L, Venkataraman AP, Dominguez-Vicent A, Petrovski G, Williams PA, Locri F, Zweifel SA, Kvanta A

doi: 10.1167/tvst.14.5.5

Cornea and Corneal Diseases

Comparison of Recurrent and Naïve Keratitis in a Cohort of 1303 Patients

J Clin Med

Kwiatkowski M, Babula E, Sikora A, Izdebska J, Skrzypecki J, Szaflik JP, Przybek-Skrzypecka J

doi: 10.3390/jcm14113760

Blindness and Vision Impairment

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study

Acta Ophthalmol

Bennebroek CAM, van Zwol J, Montauban van Swijndregt MC, Loudon SE, Groot ALW, Bauer NJC, Pott JW, Notting IC, van Sorge AJ, van Genderen MM, de Graaf P, Schouten-van Meeteren AYN, Saeed P, Porro GL

doi: 10.1111/aos.17476

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular Diseases

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

BMC Ophthalmol

Singh RP, Tabano D, Kuo BL, LaPrise A, Leng T, Kim E, Hatfield M, Garmo V

doi: 10.1186/s12886-024-03797-9

Surgery and InterventionFurther Publications

Strabismus Surgery in Patients Aged Over 80 Years: Indications, Safety, and Outcomes

Am J Ophthalmol

Yehezkeli V, Pineles SL, Demer JL, Meng Q, Velez FG

doi: 10.1016/j.ajo.2025.01.021

Ophthalmology

Impact of AI-quantified fluid dynamics on visual outcomes over 5 years in patients with treatment-naïve nAMD from the FRB! registry

Related content

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Clinical characteristics associated with complications and poor visual outcomes in ocular toxoplasmosis: Analysis of 853 patients: complications and visual outcomes in ocular toxoplasmosis

Long-Term Natural History of Treatment-Naïve Geographic Atrophy in Age-Related Macular Degeneration

Comparison of Recurrent and Naïve Keratitis in a Cohort of 1303 Patients

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

Strabismus Surgery in Patients Aged Over 80 Years: Indications, Safety, and Outcomes